July 2026 Research Update

This month added an early but clearer picture of one possible chain of events that can amplify inflammation in CAPS. In mouse models and patient cells, a specific material released by neutrophils (a kind of sticky DNA-protein web) appeared to push immune cells to release IL-1beta, a key inflammatory signal in CAPS. The work also suggests there may be more than one way this inflammation pathway can be switched on, which could help explain why blocking a single downstream step may not fully stop disease in some settings. [1]

The study focused on neutrophil extracellular traps containing citrullinated histone H3 (CitH3), which were observed to trigger IL-1beta release from mouse cells carrying a CAPS-causing Nlrp3 variant and from immune cells taken from people with CAPS. When the researchers blocked or removed PAD4 (an enzyme needed to make CitH3), CitH3 release and the IL-1beta-triggering effect were prevented in these experiments. In mice, removing PAD4 also prevented autoinflammatory disease features in a model where the Nlrp3 variant was present in neutrophils. [1]

A notable detail was that removing one pathway protein (GSDMD) did not stop autoinflammation in the Nlrp3-variant mice, because an alternate pathway involving GSDME could still be activated. In that model, deleting GSDME prevented disease features when GSDMD was absent. This helps clarify that CAPS-related inflammation in these models can route through different cell-death or inflammatory pathways, at least in experimental conditions. [1]

This is mainly early research, so it does not show that targeting PAD4 or these neutrophil traps will help people with CAPS in day-to-day care. What it does add is a more concrete explanation for how neutrophils might help drive IL-1beta release, and why the biology may not depend on a single downstream switch. What remains uncertain is how often this exact mechanism is the main driver in different people with CAPS, and whether any of these targets can be safely and effectively used in future treatments. [1]

This month strengthened the message that low-level genetic mosaicism can be an important explanation for autoinflammatory illness, including CAPS, especially when symptoms do not fit a typical inherited pattern. In a large group of people referred for suspected systemic autoinflammatory disease, deep genetic sequencing found mosaic variants in about 1 in 5 of those who received a genetic diagnosis. CAPS accounted for about a quarter of these mosaic diagnoses. [2]

The cohort included 5,530 referred patients, and systemic autoinflammatory disease was diagnosed in 403 (7.3%). Mosaic variants were identified in 83 of the 403 diagnosed patients (20.6%), with several conditions represented, including CAPS. Some mosaic variants were present at very low levels in blood testing (minor allele frequency at or below 5%), highlighting why more sensitive sequencing can matter. [2]

The study also reported that AA amyloidosis complicated the disease course in 20% of patients diagnosed with late-onset mosaic CAPS. This does not mean amyloidosis is expected for everyone with CAPS, but it helps clarify that late-onset mosaic CAPS can sometimes come with serious long-term complications in real-world clinical follow-up. [2]

These results may matter now for understanding diagnosis, because they support the idea that some people can have CAPS from a genetic change that is present in only a fraction of cells and may be missed by standard testing. The findings also help clarify that late-onset mosaic CAPS, in this referral setting, sometimes had AA amyloidosis as part of the reported course. What remains uncertain is how these rates apply outside a specialized national referral center, and how best to use mosaicism testing across different healthcare systems. [2]